Polymorphic minor transplantation antigens probably play an
Introduction
Allogeneic bone marrow transplantation (BMT)' is being successfully used for the treatment of various hematological disorders, such as aplastic anemia (1, 2) and leukemia (3, 4) . However, graft-versus-host disease (GVHD) (5, 6) and graft failure (7, 8) are major obstacles to successful transplantation, causing serious morbidity and mortality. There is a particularly high incidence of graft rejection in recipients of HLAnon-identical grafts (9, 10) . This is in accordance with the finding that the polymorphic major histocompatibility class I and class II antigens are expressed on hematopoietic progenitor cells (HPC), as shown previously (1 1-13). However, graft failures have also been observed in recipients ofHLA-identical transplants, particularly in aplastic anemia patients who had been extensively transfused before transplantation (2) .
Recently, T lymphocyte depletion ofthe marrow graft, as a method to prevent GVHD, has been found to be associated with an increase in the incidence of graft failures in HLA identical transplants (14) (15) (16) (17) . Since the incidence can be reduced by a more intensive pretransplant immunosuppressive treatment of the recipient (18-20), it is likely that an immunemediated rejection is involved in these cases. It has been demonstrated that immunocompetent lymphocytes can survive the conditioning regimen for BMT (21, 22) . Therefore, graft rejections are probably mediated by radioresistant host lymphocytes that recognize polymorphic antigenic determinants other than HLA antigens on donor marrow cells. Accordingly, mapping ofthese minor histocompatibility antigens on HPC is of major importance.
The minor histocompatibility antigen H-Y is coded for by the Y chromosome and therefore is expressed on cells of male individuals (23) . It was discovered as a transplantation antigen by Eichwald and Slimser in 1955, who found that skin grafts from male donors could be rejected by female recipients from certain strains of inbred mice (24) . In 1977, Goulmy et al. showed the HLA class I restricted recognition ofthe H-Y antigen in humans (25) . The human H-Y antigen can only be studied in vitro using cellular techniques such as cell-mediated cytotoxicity. Minor (26) .
In this study we investigated, using a cell-mediated cytotoxicity assay, the expression of the H-Y antigen on mature and immature human hematopoietic progenitor cells as well as on mature peripheral blood cells of both male and female donors. We demonstrate that the H-Y antigen is expressed on all male immature hematopoietic progenitor cells (CFU-GEMM, CFU-GM, BFU-E), and that expression diminishes during erythroid and myeloid differentiation.
Methods

Establishment ofthe anti-H-Y CTL line
The anti-H-Y CTL line was established as descnbed previously (25, 27 
CFU-GEMM
A quantity of 105 bone marrow cells was cultured in 1 ml medium containing 30% ABO-compatible human heparin plasma, 7.5% phytohemagglutinin-leukocyte-conditioned medium (34), 5% 10-3 M 2-mercaptoethanol, 5% deionized BSA, 5% human transferrin, 5% Iscove's modified Dulbecco's medium and 40% methylcellulose, 2.8% with 1 U/ml erythropoietin (2,5%) in 35 mm plastic dishes, in a fully humidified atmosphere of 5% CO2 at 370C. CFU-GEMM, defined as colonies containing at least both erythroid and myeloid cells (35) , were scored on days 14-18.
Normal values and calculations ofHPC growth 100% growth was defined as the number of colonies cultured from IO' untreated bone marrow mononuclear cells. Normal values of HPC growth in our laboratory are 269±25 for CFC day 4, 82±7 for CFPJ-GM day 7, 182±15 for CFU-GM day 10, 121±12 for BFU-E, 149±6 for CFU-E and 16±1 for CFU-GEMM (mean±SE). In cellular cytotoxicity assays the percentages of surviving HPC were calculated by dividing the total number of colonies by the number of colonies in the untreated control cultures.
Isolation ofperipheral blood cells Granulocytes. 2.5 ml peripheral blood was diluted with 7.5 ml RPMI 1640 plus 5% FBS and then mixed with 0.4 ml methylcellulose 2.25%, and allowed to sediment for 30 min. The supernatant was harvested, diluted in RPMI 1640 plus 5% FBS, and centrifuged over Ficoll-Isopaque. The sediment containing the granulocytes was then harvested, and incubated in an NH4CL solution (10 min, 0C) to lyse all residual erythrocytes. Monocytes. After separation of peripheral blood over Ficoll-Isopaque, T cells were removed by rosetting with 2-aminoethylisothiouronium bromide (AET)-pretreated sheep red blood cells (SRBC), and subsequently centrifuging the cell suspension over Ficoll-Isopaque (36) . The interphase was harvested and further enriched for monocytes by centrifugation over a Percoll gradient (1.063 g/cm3) (37) .
T, B, and non-B/non-T lymphocytes. Peripheral blood was depleted of monocytes by incubation with carbonyl-iron particles (45 min, 370C), and subsequent centrifugation over Ficoll-Isopaque (38) . The interphase cells were collected, and incubated with AET-pretreated SRBC, and again separated over Ficoll-Isopaque. B and non-B/non-T lymphocytes in the interphase, and the sediment containing the T lymphocytes were harvested separately, and incubated in an NH4CL solution (10 min, 0C) to lyse remaining SRBC. The interphase cells were then separated in a B-and a non-B/non-T lymphocyte fraction, using FITC-labeled (FAB2) anti human Ig antibodies (Nordic Immu- Purity ofthe peripheral blood cell preparations 
5'Cr-release assays
Standard 51Cr-release assays were performed as described previously (28) . Briefly, target cells were labeled with 100 GCi Na25'Cro4 for 1 h in a 37°C waterbath, washed three times with HBSS and then resuspended in RPMI plus 15% serum at a concentration of 5 X 104 viable cells/ml. A quantity of0.1 ml ofthe effector cell suspension and 0.1 ml of the target cell suspension were added to each well of a round bottomed microtiter plate at E/T ratios ranging from 40:1 to 1:1. To measure spontaneous release of 5'Cr, 0.1 ml of the target cell suspension was added to 0.1 ml RPMI plus 15% serum, without effector cells, while maximum release was determined by adding 0.1 ml ofthe target cell suspension to 0.1 ml of a Zaponine solution. Percentage lysis was determined as follows: experimental mean cpm -spontaneous release cpm/maximum release cpm -spontaneous release cpm X 100. Cold target inhibition assays were performed by adding non-5'Cr-labeled Table I . In the 5"Cr-release assay, at an E/T cell ratio of 20/1 the CTLs caused 80-90% lysis of PHA blasts from HLA-A2 or -B7 positive male donors, and showed no reactivity against PHA blasts from HLA-A2 or -B7 positive female donors (mean lysis: 7-8%). Because H-Y antigen recognition by these cytotoxic T lymphocytes is restricted by HLA-A2 or -B7 antigens (25) there is no reactivity against PHA blasts from HLA-A2 and -B7 negative male donors (mean lysis: 6%). Surface markers analysis of the anti H-Y CTL line by indirect immunofluorescence showed that 98% of the cells were activated T lymphocytes; the majority (90%) having a cytotoxic/suppressor phenotype.
Reactivity ofthe anti H-Y CTL line with HPC. When the anti H-Y CTL line was incubated for 4 h with bone marrow mononuclear cells, a dose-dependent inhibition of the growth of CFU-GM, BFU-E and CFU-GEMM from HLA-A2 or -B7 positive male donors was found at E/T ratios varying from 1:2 to 4:1 (Fig. 1) . At E/T ratio 4:1 virtually no growth was observed: 6±2% (mean±SE) growth of CFU-GM, 7±5% growth of BFU-E and 4±2% growth of CFU-GEMM, as compared to the untreated control cultures, indicating that the H-Y antigen is expressed on these HPC. There was only partial inhibition of the growth of CFU-E (60±15% growth at the highest E/T ratio). When bone marrow cells from HLA-A2 or -B7 positive female donors were tested, growth of CFU-GM, CFU-E, BFU-E, and CFU-GEMM was not inhibited at the effector/ target cell ratios used (colony growth at E/T ratio 4:1: 102+4%, 95±8%, 114+13%, and 85±17%, respectively). The expression of the H-Y antigen on immature myeloid progenitor cells (CFU-GM day 10 and day 7) was compared with the more mature myeloid HPC (CFC day 4) of male bone marrow donors. As shown in Table II , inhibition of myeloid HPC growth by the anti-H-Y CTL line diminishes during maturation of the progenitors, since there was only 6±6% growth of CFU-GM day 10 and 14±5% growth of CFU-GM day 7 as compared to 45±3% growth of CFC day 4. Control cultures in which female bone marrow cells were used as targets did not show inhibition of growth by the anti-H-Y CTL line.
To exclude the possibility that the observed inhibition was nonspecific, CTLs and bone marrow cells were plated without preincubation. Table III shows that addition of the CTLs to the bone marrow culture at an effector/target cell ratio of 4:1, without incubation before plating, did not result in a significant inhibition of hematopoietic progenitor cell growth, indicating that intimate effector/target cell contact was required for the elimination of the HPC.
The lysis of the HPC by the anti H-Y CTL line was HLA class I restricted: Fig. 2 shows that normal growth ofCFU-GM was observed (115±10%) when bone marrow cells from HLA-A2 and -B7 negative male donors were incubated with the anti H-Y CTL line at an effector/target cell ratio of4:1. To investigate whether the H-Y antigen can also be recognized on HPC in conjunction with other restriction elements we performed some experiments using a recently isolated HLA-Al restricted anti H-Y cytotoxic T lymphocyte line. Extended population studies showed that this CTL line has characteristics similar to the HLA A2/B7 restricted cell line, except that only cells from HLA-AI positive male donors are lysed (data Vertical bars indicate SE. not shown). As shown in Table IV , this CTL line lysed HLA-A1 positive male donor HPC but did not inhibit HLA-Al positive female donor HPC. Finally, the expression of the H-Y antigen on mature peripheral blood cells was studied (Table V) . We could not demonstrate any lysis of mature granulocytes and erythrocytes of HLA-A2 or -B7 positive male donors by the anti-H-Y CTL line. However, when granulocytes were used as competitors in a cold target inhibition assay, they were able to induce some inhibition of lysis of hot targets, although it was less than inhibition oflysis by cold T lymphocytes (Table VI ). This indicates that the H-Y antigen is to some extent expressed on mature granulocytes. The H-Y antigen was found to be clearly expressed on monocytes, T, B, and non-B/non-T lymphocytes.
Discussion
In allogeneic bone marrow transplantation, residual T lymphocytes or other immune cells that have survived chemotherapy and irradiation may recognize certain polymorphic antigenic determinants on HPC of the donor, leading to an immune-mediated rejection of the bone marrow graft (7, 8, 14) . Identification of the polymorphic antigens that could serve as target structures in graft rejection ultimately opens the possibility to match for these histocompatibility antigens. Storb et al. (8, 39) previously reported that male sex of the donor is associated with a greater risk of graft rejection after allogeneic BMT in patients with aplastic anemia. More recently, Kernan et al. (40) identified male donor sex as a risk factor for graft-failure following T cell-depleted bone marrow transplants. Since graft failure after BMT may often be due to the recognition of unshared polymorphic antigens by the host, the rejection of transplants from male donors by female recipients may be due to recognition of the male-specific minor histocompatibility antigen H-Y on male donor bone marrow cells. In fact, following the rapid rejection by a female recipient of a bone marrow graft from her HLA-identical male sibling, it has been possible to elicit an HLA-restricted H-Y specific cytotoxic T cell response from the peripheral blood of that patient in mixed lymphocyte cultures (25) . However, it has not been demonstrated so far that the H-Y antigen is expressed on hematopoietic progenitor cells, and can serve as a target structure for cytotoxic T cell responses. Our results show that the H-Y antigen is expressed on CFU-GM, BFU-E, and CFU-GEMM (Fig. 1) , and that the cell-mediated cytotoxicity ofthe CTL line directed against this antigen on HPC, is HLA class I restricted (Table I, Fig. 2 the context of various HLA-antigens. The effector mechanism by which recognition of the H-Y antigen on HPC of male donors resulted in growth inhibition of HPC, appeared to be clearly dependent on cell-cell contact, since it was not possible to induce growth inhibition without preincubation of CTLs and bone marrow cells before plating (Table III) . Therefore, it is unlikely that this effect is due to release of growth inhibitory factors in the medium by the cytotoxic cells. With regard to CFU-E, the recognition of the H-Y antigen by the anti H-Y CTL line was less clear. This may indicate that the expression of the H-Y antigen diminishes during maturation from early (BFU-E) to late (CFU-E) erythroid progenitor cells. The absence of lysis of mature peripheral blood erythrocytes was expected since these cells do not express HLA class I antigens (41) , and therefore cannot be recognized by the CTL line.
A similar decrease in recognition of the H-Y antigen was also observed during myeloid differentiation: whereas there was maximal inhibition of growth of the early myeloid progenitors CFU-GM day 10, there was only partial inhibition of growth of late myeloid progenitors (CFC day 4), and no obvious recognition of the H-Y antigen on mature granulocytes in standard 51Cr-release assays (Table V) . On the other hand cold target inhibition studies indicated that the H-Y antigen is expressed to some extend on mature granulocytes (Table VI) . Several factors may contribute to the diminished recognition of the H-Y antigen during myeloid differentiation. Besides a decreased expression of the H-Y antigen, we cannot exclude that this decrease in growth inhibition is partly due to a diminished expression of the HLA class I determinants, since there is evidence that the expression of HLA class I antigens diminishes during myeloid differentiation (42, 43) although they are clearly present on mature granulocytes (41, 43) . Alternatively, it may be that more mature myeloid cells are simply less sensitive targets for cell mediated lysis. The H-Y antigen was clearly expressed on other mature peripheral blood cells, since monocytes, T, B and non-B/non-T lymphocytes were effectively lysed by the anti H-Y CTL line (Table V) .
In conclusion, these results clearly show that the H-Y antigen can serve as a target structure on HPC for cytotoxic T cell responses, and may therefore conceivably play a role in bone marrow graft rejection in man. Such a risk could be particularly pertinent for HLA-A2 positive female recipients, since there seems to be a relationship between anti-H-Y responsiveness and the presence of the HLA-A2 antigen (44) . In renal transplantation, for example, it was found that female recipients of male donor kidneys had a decreased transplant survival if recipient and donor shared the HLA-A2 antigen (45). Furthermore, in recent years we isolated anti-H-Y CTL lines from five different patients, four of which were found to be restricted by HLA-A2 while only one CTL-line showed a different restricting element, i.e., HLA-Al (unpublished data). Although these numbers are small they may indicate that HLA-A2 restricted recognition of the H-Y antigen may be more frequent than H-Y antigen recognition in the context of other HLA-antigens. This may implicate that, in particular after T cell depletion of bone marrow grafts, HLA-A2 positive female recipients of a bone marrow graft from an HLA-A2 positive male donor may be at greater risk of rejecting their transplants, especially if they have been extensively transfused or gave birth to male children.
